Diagnostic performance, stability, and acceptability of self-collected saliva without additives for SARS-CoV-2 molecular diagnosis.

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the coronavirus disease 2019 (COVID-19), leading to a global pandemic. The molecular diagnosis of this virus is mostly performed by collecting upper respiratory samples, which has many disadvantages, including patient discomfort and the need for trained healthcare professionals. Although saliva has emerged as a more comfortable sample, the use of additives to preserve viral RNA is expensive and, in some cases, difficult for self-collection. METHOD: This study evaluated the diagnostic performance by RT-PCR and stability of self-collected saliva using wide-mouth specimen collection cups without stabilization and/or inactivation buffers for SARS-CoV-2 detection, compared to nasopharyngeal samples and saliva collected with additives. Additionally, the study assessed the acceptability of this sample collection method among participants and healthcare personnel. RESULTS: The study included 1281 volunteers with a 24.6% positive infection rate. Saliva demonstrated comparable diagnostic performance to nasopharyngeal samples, with a sensitivity of 87.6% and specificity of 99.6%, for a total percent agreement of 96.4%. The study also showed that viral RNA in saliva remained stable for at least 72 h at different temperatures. Notably, saliva samples without additives exhibited a lower RdRp Ct compared to samples with additives, suggesting that the absence of stabilization and/or inactivation buffers does not significantly affect its performance. The study highlighted the acceptability of saliva among patients and healthcare personnel due to its noninvasive nature and ease of collection. CONCLUSIONS: This research supports the implementation of self-collected saliva as a comfortable and user-friendly alternative sample for SARS-CoV-2 diagnosis.

Prevalencia de hipertensión arterial en pacientes pediátricos hospitalizados / Prevalence of arterial hypertension in pediatric hospitalized patients

Resumen Objetivo: Establecer la prevalencia de hipertensión arterial (HTA) en los pacientes pediátricos hospitalizados en un centro hospitalario de tercer nivel de Medellín, Colombia, durante seis años. Métodos: Se hizo un estudio descriptivo de corte transversal que revisó información retrospectiva obtenida de los registros de las historias clínicas de pacientes menores de 18 años hospitalizados en el Hospital Pablo Tobón Uribe de Medellín, Colombia. Resultados: De un total de 382 pacientes pediátricos hospitalizados en el periodo estudiado se obtuvo una prevalencia de HTA del 30.6%, la de hipertensión sistólica fue 23.6% y la de diastólica 20.7%. Los niños menores de cinco años, el uso de vancomicina y la estancia en cuidado crítico aumentan significativamente el riesgo de presentar hipertensión durante la hospitalización. Conclusiones: En pediatría la frecuencia de HTA en pacientes hospitalizados es elevada, mayor a la prevalencia reportada en pacientes ambulatorios. Se debe reconocer el grupo de mayor riesgo y los factores potencialmente modificables, así como definir el inicio de tratamiento de forma oportuna. Las complicaciones son bajas, excepto la hipertrofia ventricular izquierda, por lo que es necesario un seguimiento a largo plazo.

Abstract Objective: To establish the prevalence of arterial hypertension in pediatric patients hospitalized in a tertiary hospital center in Medellin, Colombia for 6 years. Methods: A descriptive cross-sectional study was carried out that reviewed retrospective information obtained from the clinical records of patients under 18 years of age hospitalized at the Pablo Tobón Uribe Hospital in Medellín. Results: From a total of 382 pediatric patients hospitalized in the studied period, a prevalence of hypertension of 30.6% was found. Systolic hypertension prevalence was 23.6% and diastolic 20.7%. Age under 5, treatment with vancomycin and critical care admission increased the risk of being hypertensive during hospitalization. Conclusions: In children the frequency of hypertension in hospitalized patients is higher than the prevalence reported in outpatients. The highest risk group and potentially modifiable factors must be recognized and treatment administered in a timely manner. Secondary complications are low, except for left ventricular hypertrophy, which requires long-term follow-up.

Prevalence of arterial hypertension in pediatric hospitalized patients.

OBJECTIVE: To establish the prevalence of arterial hypertension in pediatric patients hospitalized in a tertiary hospital center in Medellin, Colombia for 6 years. METHODS: A descriptive cross-sectional study was carried out that reviewed retrospective information obtained from the clinical records of patients under 18 years of age hospitalized at the Pablo Tobón Uribe Hospital in Medellín. RESULTS: From a total of 382 pediatric patients hospitalized in the studied period, a prevalence of hypertension of 30.6% was found. Systolic hypertension prevalence was 23.6% and diastolic 20.7%. Age under 5, treatment with vancomycin and critical care admission increased the risk of being hypertensive during hospitalization. CONCLUSIONS: In children the frequency of hypertension in hospitalized patients is higher than the prevalence reported in outpatients. The highest risk group and potentially modifiable factors must be recognized and treatment administered in a timely manner. Secondary complications are low, except for left ventricular hypertrophy, which requires long-term follow-up.

OBJETIVO: Establecer la prevalencia de hipertensión arterial (HTA) en los pacientes pediátricos hospitalizados en un centro hospitalario de tercer nivel de Medellín, Colombia, durante seis años. MÉTODOS: Se hizo un estudio descriptivo de corte transversal que revisó información retrospectiva obtenida de los registros de las historias clínicas de pacientes menores de 18 años hospitalizados en el Hospital Pablo Tobón Uribe de Medellín, Colombia. RESULTADOS: De un total de 382 pacientes pediátricos hospitalizados en el periodo estudiado se obtuvo una prevalencia de HTA del 30.6%, la de hipertensión sistólica fue 23.6% y la de diastólica 20.7%. Los niños menores de cinco años, el uso de vancomicina y la estancia en cuidado crítico aumentan significativamente el riesgo de presentar hipertensión durante la hospitalización. CONCLUSIONES: En pediatría la frecuencia de HTA en pacientes hospitalizados es elevada, mayor a la prevalencia reportada en pacientes ambulatorios. Se debe reconocer el grupo de mayor riesgo y los factores potencialmente modificables, así como definir el inicio de tratamiento de forma oportuna. Las complicaciones son bajas, excepto la hipertrofia ventricular izquierda, por lo que es necesario un seguimiento a largo plazo.

Actualización en lesión renal aguda inducida por contraste en pediatría

Contexto: la lesión renal aguda inducida por contraste se ha convertido en un tema de gran interés en la comunidad médica a nivel mundial, siendo la tercera causa de lesión renal aguda adquirida en el hospital. Objetivo: el presente artículo presenta una revisión de la literatura con el fin de actualizar los conceptos de esta patología en el personal de la salud que está en contacto con la población pediátrica y que es sometida a procedimientos con medios de contraste. Metodología: en esta revisión narrativa de la literatura, presentamos la definición, los factores de riesgo, el enfoque clínico y las medidas preventivas de la nefropatía inducida por contraste en pediatría. Resultados: se define que hay un deterioro en la función renal aguda después de la administración del medio de contraste en donde se excluyen otras posibles etiologías y se establece una verdadera relación causal con la sustancia. Los factores de riesgo son múltiples, sin embargo, factores estrictamente relacionados en los niños no han sido establecidos en su totalidad. El abordaje de los pacientes que van a ser sometidos a estudios con medios de contraste inicia desde una historia clínica, un examen físico y unas medidas de laboratorio que permiten evaluar el estado basal de cada paciente para instaurar medidas preventivas. Por su parte, las estrategias de prevención de esta condición son múltiples, sin embargo, no existen guías basadas en la evidencia acerca de esta condición en el paciente pediátrico. Conclusiones: el artículo presenta una revisión de la literatura sobre lesión renal aguda para actualizar los conceptos de esta patología en el personal de la salud que está en contacto con la población pediátrica que se somete a procedimientos con medios de contraste.

Context: Contrast-induced acute kidney injury has become a topic of great interest in the medical community worldwide, being the third cause of hospital-acquired acute kidney injury. Purpose: This article presents a review of the literature in order to update the concepts of this pathology in health personnel who are in contact with the pediatric population that undergoes procedures with contrast media. Methodology: In this narrative review of the literature, we present the definition, risk factors, clinical approach, and preventive measures of contrast-induced nephropathy in pediatrics. Results: It is defined as a deterioration in acute renal function after the administration of the contrast medium where other possible etiologies are excluded and a true causal relationship with the substance is established. The risk factors are multiple; nevertheless; Strictly related factors in children have not been fully established. The approach to patients who are going to undergo studies with contrast media begins with a clinical history, physical examination, and laboratory measurements that allow the baseline status of each patient to be evaluated in order to establish preventive measures. The prevention strategies of this condition are multiple; however, there are no evidence-based guidelines on this condition in pediatric patients. Conclusions: This article presents a review of the literature in order to update the concepts of acute kidney injury in health personnel who are in contact with the pediatric population that undergoes procedures with contrast media.

Disseminated coelomic xanthogranulomatosis in eclectus parrots (Eclectus roratus) and budgerigars (Melopsittacus undulatus).

Xanthogranulomatosis is an inflammatory lesion characterized by lipid-containing macrophages, extracellular lipid, hemorrhage, and necrosis. We describe disseminated intracoelomic xanthogranulomatosis in 5 eclectus parrots (Eclectus roratus) and 2 budgerigars (Melopsittacus undulatus). Postmortem, clinicopathologic, and historical case material was reviewed. Ages ranged from 3 to 24 years; there were 5 males and 2 females. Table food was included in the diet of 3/5 cases, and animal products were included in 2/3 cases. Common clinicopathologic abnormalities included leukocytosis (4/5 cases) and elevated concentrations of bile acids (3/4 cases) and cholesterol within 6 months prior to death (2/4 cases). At postmortem examination, all 7 birds had grossly visible, irregular, soft, tan to yellow, amorphous plaques distributed on the surfaces of the viscera and body wall. Histologic evaluation and oil red O stain revealed xanthogranulomatous inflammation with phagocytized and extracellular lipid, necrosis, cholesterol clefts, fibrosis, and mineralization. Infectious agents were not identified with special stains in all cases. Concurrent hepatobiliary disease was present in 6/7 cases, and 6/7 had lipid accumulation within the parenchyma of various visceral organs. Five cases had atherosclerosis of great vessels. We describe a unique form of disseminated coelomic xanthogranulomatosis in 2 psittacine species. This condition should be recognized as a differential diagnosis in cases of disseminated coelomic mass formation and coelomic distension in psittacine birds, particularly in eclectus parrots and budgerigars.

Enzymatic synthesis of capric acid-rich structured lipids and their effects on mice with high-fat diet-induced obesity.

The objective of this study was to produce structured lipids (SLs) by enzymatic acidolysis using Rhizopus oryzae lipase covalently immobilized in a low-cost material. Grape seed oil was used to synthesize SLs containing the medium-chain fatty acid (C10:0) capric acid. SL synthesis led to 38.8% medium-chain fatty acid incorporation with 5 reuses of the enzymatic derivative. The reaction conditions for the synthesis of MLM-TAGs (triacylglycerols with one long- and two medium-chain acyl residues) were at a molar ratio of fatty acid:oil of 3:1, performed at 40 °C and lipase immobilized load of 5% (w/w). The in vivo effects of SLs were studied in Swiss mice fed premade diets: control (C) diet, high-fat diet (HFD) with 100% lipid content as lard, HFD with 50% lipid content as grape seed oil (HG) or HFD with 50% lipid content as capric acid-containing SLs produced from grape seed oil (HG-MCT). Mice from HG and HG-MCT groups had decreases in body weight gain and reductions in the weights of white adipose tissues. In addition, HG and HG-MCT mice had low plasma levels of glucose and total cholesterol, and improvements in the glucose tolerance. HG and HG-MCT diets have remarkable antioxidant properties, since low plasma levels of TBARS (thiobarbituric acid reactive substances, biomarkers of lipid peroxidation) were found in mice fed these diets. Interestingly, TBARS levels in HG-MCT mice were further decreased than values of HG mice. Mice fed HG and HG-MCT diets also showed preservation in the activity of the antioxidant enzyme paraoxonase 1. Both HG and HG-MCT diets promoted reduction of IL-6 and IL-10 production by splenocytes. The capric acid-containing SLs produced from grape seed oil emerges as a functional oil capable to mitigate obesity complications resulting from oxidative stress and inflammation.

Comparative Evaluation of the Effects of Consumption of Colombian Agraz (Vaccinium meridionale Swartz) on Insulin Resistance, Antioxidant Capacity, and Markers of Oxidation and Inflammation, Between Men and Women with Metabolic Syndrome.

The metabolic syndrome (MS) is a constellation of related factors that increases the risk of developing cardiovascular diseases. Vaccinium meridionale Swartz contains polyphenols that could modulate some components of MS. Epidemiological and intervention studies have shown differences between men and women in MS components and antioxidant capacity. The objective of this study is to compare between men and women with MS the effects of agraz consumption on insulin resistance, antioxidant capacity, and markers of oxidation and inflammation. Men and women diagnosed with MS according to the Adult Treatment Panel III criteria were recruited in a double-blind, crossover study of 12 weeks. Participants were assigned to consume agraz nectar or placebo over 4 weeks. After 4 weeks of washout, they were switched to the alternative treatment. At the end of each period, the components of the MS, insulin resistance, antioxidant capacity, and some oxidative (oxidized low-density lipoprotein [oxLDL]; thiobarbituric acid reactive substances) and inflammatory (high-sensitive C-reactive protein [hs-CRP]) markers were evaluated. After consuming agraz, there was a tendency to increase the levels of antioxidants and to reduce the levels of hs-CRP in both genders. In addition, women who increased their serum phenols after consuming agraz had a significant reduction in insulin resistance, which was different from the results in men. Regarding men, those who increased their serum antioxidant capacity after consuming agraz had a better effect on the reduction of oxLDL levels that was significant compared to women. There are important differences between genders in the effects of agraz consumption in adults with MS.

Frequency of arterial hypertension, diabetes and dyslipidemia in children after kidney transplants. / Frecuencia de hipertensión arterial, diabetes y dislipidemia en niños con trasplante renal

BACKGROUND: Pediatric kidney transplant patients have an increased risk of developing arterial hypertension, dyslipidemia, carbohydrate intolerance and diabetes mellitus, risk factors associated with increased cardiovascular morbidity and mortality. OBJECTIVE: This study evaluates the frequency of arterial hypertension, dyslipidemia and alteration in carbohydrate metabolism in a cohort of pediatric kidney transplant patients during 2006-2016 at the Pablo Tobon Uribe Hospital, in Colombia. MATERIAL AND METHODS: Retrospective descriptive study in which descriptive statistics were used. Additionally, a bivariate analysis was performed to compare patients according to the outcome of arterial hypertension, dyslipidemia and alteration in carbohydrate metabolism. RESULTS: From a total of 48 pediatric kidney transplants in the period studied, complete information was obtained from 43 patients at one year of follow-up. There was a post-transplant frequency of hypertension of 86%, dyslipidemia 48%, carbohydrate intolerance 14% and diabetes of 2%. CONCLUSIONS: In the evaluated cohort a high frequency of arterial hypertension and dyslipidemia was found after kidney transplantation. The development of early diagnosis and treatment guidelines is suggested to reduce the impact of these diseases associated with cardiovascular risk in adult life.

INTRODUCCIÓN: Los pacientes pediátricos con trasplante renal tienen un riesgo incrementado de desarrollar hipertensión arterial, dislipidemia, intolerancia a los hidratos de carbono y diabetes mellitus, factores de riesgo que se asocian con una mayor morbilidad y mortalidad cardiovascular. OBJETIVO: Evaluar la frecuencia de hipertensión arterial, dislipidemia y alteración en el metabolismo de los hidratos de carbono en una cohorte de pacientes pediátricos con trasplante renal durante 2006-2016 en el Hospital Pablo Tobon Uribe, en Colombia. MATERIAL Y MÉTODOS: Estudio descriptivo retrospectivo en el cual se utilizó estadística descriptiva. Adicionalmente se realizó análisis bivariado para comparar pacientes según el desenlace hipertensión arterial, dislipidemia y alteración en el metabolismo de los hidratos de carbono. RESULTADOS: De un total de 48 trasplantes renales pediátricos en el periodo estudiado, se obtuvo información completa de 43 pacientes al año de seguimiento. Se observó una frecuencia postrasplante de hipertensión arterial del 86%, de dislipidemia del 48%, de intolerancia a los hidratos de carbono del 14% y de diabetes del 2%. CONCLUSIONES: En la cohorte evaluada se encontró una alta frecuencia de hipertensión arterial y dislipidemia postrasplante renal. Se sugiere el desarrollo de guías de diagnóstico precoz y tratamiento que permitan disminuir el impacto de estas enfermedades asociadas a riesgo cardiovascular en la vida adulta.

Effect of Agraz (Vaccinium meridionale Swartz) on High-Density Lipoprotein Function and Inflammation in Women with Metabolic Syndrome.

Metabolic syndrome (MetS) is associated with low-grade inflammation and high-density lipoprotein (HDL) dysfunction. Polyphenol-rich foods may improve these alterations. Agraz is a fruit rich in polyphenols (mainly anthocyanins); however, there is limited information about its effects on human health. We evaluated the effects of agraz consumption as compared to placebo on HDL function and inflammation in women with MetS. Forty volunteers (25⁻60 years) were included in this double-blind crossover study. Women consumed agraz or placebo over 4 weeks; separated by a 4-week washout period. HDL function (apoliprotein-A1; paraoxonase 1 (PON1) activity; cholesterol efflux capacity), oxidative stress (myeloperoxidase (MPO), advanced oxidation protein products) and inflammatory markers (serum cytokines/chemokines and peripheral blood mononuclear cell nuclear factor-kB) were measured after each period. Compared to placebo, agraz consumption did not significantly change any of the biomarkers measured. Interestingly, only after agraz period there were significant positive correlations between PON1 activities and cholesterol efflux. Additionally, there were significant inverse correlations between changes in inflammatory markers and HDL function markers and positive correlations with oxidative markers. Although polyphenol-rich foods have been shown to be beneficial for certain conditions; polyphenol-rich agraz fruit consumption did not impact inflammation and HDL function in the current study of women with MetS.

Evaluation of Agraz Consumption on Adipocytokines, Inflammation, and Oxidative Stress Markers in Women with Metabolic Syndrome.

Metabolic syndrome (MetS) is characterized by increased oxidative stress and a pro-inflammatory state. Vaccinium meridionale Swartz (known as "agraz") is a berry rich in polyphenolic compounds with demonstrated antioxidant activity and anti-inflammatory effects in preclinical studies. The aim of this study was to evaluate the effects of agraz consumption on inflammatory and oxidative stress markers in women with MetS. Forty women with MetS (47 ± 9 years) were randomly assigned to consume daily either 200 mL of agraz nectar or placebo over four weeks in a double-blind, cross-over design study, separated by a 4-week washout period. Metabolic and inflammatory markers in serum and antioxidant/oxidative stress markers in serum and urine were assessed at the end of each period. Serum antioxidant capacity measured by the 2,2-diphenyl-1-picrylhydrazyl (DPPH) method was significantly higher (p = 0.028), while urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) was lower (p = 0.041) after agraz consumption, compared to placebo. In conclusion, consumption of agraz during four weeks increased serum antioxidant capacity and decreased a marker of DNA oxidative damage in women with MetS, compared to placebo. These results suggest that agraz consumption may play a protective role in patients with MetS.

Cardiometabolic risk factors in preschool children with abdominal obesity from Medellín, Colombia.

Background Abdominal obesity (AO) is linked to inflammation and insulin resistance (IR). However, there is limited information on whether preschoolers with AO present these risk factors. We evaluated the association between AO and cardiovascular risk factors in preschoolers. Methods We enrolled 232 children (2-5 years), of whom 50% had AO. Serum total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-c), high-density lipoprotein-cholesterol (HDL-c), triglycerides (TG), apolipoprotein B (Apo-B) and apolipoprotein A-1 (Apo-A1), glucose, insulin, high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, IL-1ß, monocyte chemoattractant protein (MCP-1/CCL2), leptin, adiponectin, vascular cell adhesion molecule (VCAM-1/CD106) and intercellular adhesion molecule (ICAM-1/CD54) were measured. The homeostatic model assessment of IR (HOMA-IR) was calculated. We analyzed these variables according to the presence of AO and other metabolic syndrome (MetS) components. Results A total of 75.8% of children with AO had one or more risk factors for MetS. Children with AO had significantly higher body mass indexes (BMIs), insulin, HOMA-IR, TG, very low-density lipoprotein-cholesterol (VLDL-c) and TC/HDL-c ratio and lower HDL-c, compared to children without AO; but there were no differences in inflammatory markers. After adjusting for BMI, sex and age, the differences between groups were not significant for any variable. Waist circumference (WC) was correlated with insulin (r=0.547; p<0.001), TG (r=0.207; p=0.001), ICAM-1 (r=0.213; p=0.039), hs-CRP (r=0.189; p=0.015) and glucose (r=0.187; p=0.004). After adjusting for BMI, age and sex, AO plus one MetS component contributed to individual variation in glucose, insulin, HOMA-IR and TG. Conclusions AO in preschool children is associated with greater IR and atherogenic lipid profiles, although these findings seem to be more related to general obesity than just central obesity. In addition, our data suggest that IR may precede the elevation of systemic cytokines in obese children, unlike findings in adults. More studies in pediatric populations are needed to elucidate these associations.

Inmunosupresores y principales complicaciones en el trasplante renal pediátrico / Imunossupressores e principais complicações no transplante renal pediátrico / Immunosuppressive drugs and major complications in pediatric renal transplantation

El trasplante renal pediátrico es el tratamiento de elección en los niños con enfermedad renal crónica terminal. Muchos agentes se utilizan en dos regímenes de terapia inmunosupresora, primero en una fase de inducción y posteriormente para el mantenimiento. Existen dos estrategias para disminuir el riesgo de rechazo del injerto renal: la primera consiste en suministrar altas dosis de los inmunosupresores convencionales, y la segunda, en la utilización en la fase de inducción de anticuerpos monoclonales o policlonales contra antígenos de los linfocitos T. Los dos anticuerpos policlonales más usados son las globulinas antitimocito de caballo (ATGAM) y de conejo (rATG). Los anticuerpos monoclonales más usados son aquellos contra el receptor de IL-2 (basiliximab y daclizumab) y el dirigido contra el antígeno CD52 (alemtuzumab). La terapia de mantenimiento consiste en un esquema que combina el uso de tres drogas inmunosupresoras convencionales: glucocorticoides, inhibidores de la calcineurina, inhibidores de mTOR y antiproliferativos. Entre las principales complicaciones del trasplante renal pediátrico están: rechazo agudo del injerto, infecciones virales (por poliomavirus-BK y citomegalovirus) y aparición del trastorno linfoproliferativo postrasplante (PTLD, por la sigla en inglés de Post-transplant lymphoproliferative disorder).

Pediatric renal transplantation is the treatment of choice in children with chronic kidney disease. Many agents are available for immunosuppressive therapy, which are used in two different regimes: first for the induction phase, and then for maintenance. There are two strategies for reducing the risk of renal graft rejection: the first is the use of high doses of conventional immunosuppressive agents, and the second is the use in the induction phase of monoclonal or polyclonal antibodies against antigens of T cells. The two most frequently used polyclonal antibodies are horse and rabbit anti-thymocyte globulins, ATGAM and rATG, respectively. The most frequently used monoclonal antibodies are those against IL-2 receptor (basiliximab and daclizumab) and the one against antigen CD52 (alemtuzumab). Maintenance therapy is a scheme that combines the use of three conventional immunosuppressive drugs: glucocorticoids, calcineurin inhibitors, mTOR inhibitors and antiproliferatives. The following are among the major complications of renal transplantation: acute graft rejection, viral infection (cytomegalovirus and BK polyomavirus) and appearance of PTLD (posttransplant lymphoproliferative disorder).

O transplante renal pediátrico é o tratamento de eleição nas crianças com doenças renais crónica terminal. Muitos agentes utilizam em dois regimes de terapia imunossupressora, primeiro em uma fase de indução e posteriormente para a manutenção. Existem duas estratégias para diminuir o risco de rejeição do inserto renal: a primeira consiste em subministrar altas dose dos imunossupressores convencionais, e a segunda, na utilização na fase de indução de anticorpos monoclonais ou policlonais contra antígenos dos linfócitos T. os dois anticorpos policlonais mais usados são as globulinas antitimócito de cavalo (ATGAM) e de coelho (rATG). Os anticorpos monoclonais mais usados são: aqueles contra o receptor de IL-2 (basiliximab e daclizumab) e o dirigido contra o antígeno CD52 (alemtuzumab). A terapia de manutenção consiste num esquema que combina o uso de três drogas imunossupressoras convencionais: glicocorticoides, inibidores da calcineurina, inibidores de mTOR e antiproliferativos. Entre as principais complicações do transplante renal pediátrico estão: rejeição aguda do inserto, infecções virais (por poliomavirus-BK e citomegalovírus) e aparição do transtorno linfoproliferativa pós-transplante (PTLD, pela sigla em inglês de Post-transplant lymphoproliferative disorder).

Plasmaféresis en rechazo agudo del injerto renal mediado por anticuerpos. Estudio realizado en el Hospital Pablo Tobón Uribe, Medellín, Colombia. Año 2005-2015 / Plasmapheresis in antibody-mediated renal allograft rejection. Experience of Pablo Tobon Uribe, Medellin, Colombia. Year 2005-2015

Introducción: el rechazo agudo mediado por anticuerpos es una complicación que se presenta luego del trasplante renal y es una causa importante de pérdida del injerto. La plasmaféresis es una de las terapias utilizadas para su tratamiento, algunos estudios sugieren mejor supervivencia del injerto renal con el uso de plasmaféresis; sin embargo su evidencia es débil. Objetivo: este estudio tiene como objetivo describir la experiencia del uso de plasmaféresis en el rechazo agudo mediado por anticuerpos. Materiales y Métodos: estudio descriptivo retrospectivo realizado en el Hospital Pablo Tobón Uribe entre agosto de 2005 y junio de 2015 en pacientes con diagnóstico de rechazo agudo mediado por anticuerpos, quienes recibieron entre tres y nueve sesiones de plasmaféresis. Resultados: se realizaron un total de 769 trasplantes renales; de los cuales 26 pacientes presentaron rechazo agudo mediado por anticuerpos y recibieron plasmaféresis como parte del tratamiento. Todos los pacientes recibieron terapia de inducción al momento del trasplante y en el 80,8% la terapia de mantenimiento utilizada fue tacrolimus-micofenolato-prednisolona. El rechazo mediado por anticuerpos se presentó en forma temprana en el 61,5% de los pacientes. A seis y doce meses el 44% y 53,8% de los pacientes respectivamente presentaron pérdida del injerto renal; las complicaciones se presentaron en el 53,8% de los pacientes, las cuales fueron hipocalcemia, hipotensión y anafilaxia. Conclusión: en esta cohorte el uso de plasmaféresis en el rechazo agudo mediado por anticuerpos no logró evitar la pérdida del injerto renal en el 50% de los pacientes; se sugiere adicionar a esta terapia otras alternativas de tratamiento entre ellas, la inmunoglobulinas intravenosas, rituximab, eculizumab y bortezomib. MÉD.UIS. 2016;29(2):41-8.

Background: antibody-mediated renal allograft rejection is a complication after kidney transplantation, and it has poor prognosis for graft survival. Plasmapheresis has been used with controversial results; few trials indicate a trend towards superior graft survival in patients receiving this treatment; however, the evidence remains weak. Objetive: the aim of this study was to describe the experience in treating Antibody-mediated renal allograft rejection with plasmapheresis in kidney transplant recipients. Methods: retrospective and descriptive study of the patients that underwent three to nine session of plasmapheresis as a treatment of severe Antibody-mediated renal allograft rejection in Pablo Tobón Uribe Hospital. Results: between August 2005 and June 2015, 769 patients underwent kidney transplantation at our institution; 26 patients received plasmapheresis as part of the treatment for Antibody-mediated renal allograft rejection. All patients received induction therapy. Maintenance therapy used was tacrolimus, mycophenolic acid and steroids in 80,8% of the patients and cyclosporine, micophenolic acid and steroids in 19,2%. Antibody mediated rejection had an early onset in 61,5% of the cases. At six and 12 months after therapy, 44% and 53,8% patients respectively were back on dialysis. Complications were reported in 53,8% of the patients (hypocalcaemia, hypotension and anaphylaxis). Conclusion: in this cohort, 50% of patients who received Plasmapheresis as therapy for severe Antibody-mediated renal allograft rejection presented loss graft after one year of follow up. It is necessary adding to this therapy new treatment alternatives, among them intravenous immunoglobulin, rituximab, eculizumab and bortezomib. MÉD.UIS. 2016;29(2):41-8.

Hallazgos nefro-urológicos postnatales de pacientes con diagnóstico prenatal de hidronefrosis evaluados en un hospital de cuarto nivel de complejidad / Postnatal nephro-urology findings of patients with prenatal diagnosis of hydronephrosis

No es clara la repercusión clínica de la hidronefrosis. Este estudio busca determinar las características de las imágenes diagnósticas de los pacientes con hidronefrosis prenatal y determinar si el valor del diámetro anteroposterior de la pelvis renal puede identificar la presencia de malformaciones urológicas posnatales y la necesidad de cirugía. Materiales y métodos: estudio transversal en el que se revisaron las historias clínicas de todos los pacientes con edades entre 0 y 5 años de edad, con diagnóstico prenatal de hidronefrosis, quienes consultaron a un hospital de cuarto nivel de complejidad en la ciudad de Medellín - Colombia. Cada unidad renal se evaluó en forma independiente. Resultados: en total se estudiaron 135 unidades renales de 97 pacientes. No se encontró hidronefrosis posnatal en el 17,8 %. Al seguimiento, el 85 % de los pacientes con estenosis pieloureteral y 90 % de los pacientes con valvas de uretra posterior fueron clasificados prenatalmente como hidronefrosis moderada a grave. Por el contrario, el 41,4 % de los riñones con diagnóstico de reflujo vesico-ureteral fueron clasificados como hidronefrosis leve, 34,5 % moderada y 24,1 % grave. El 56,3 % de los riñones necesitaron algún tipo de cirugía. El 26 % de las hidronefrosis clasificadas como leves necesitaron algún procedimiento quirúrgico. Un diámetro anteroposterior de la pelvis renal de 10,5 mm tuvo una sensibilidad de 67 % y una especificidad de 71,2 % para la detección de malformaciones nefro-urológicas. Conclusión: la hidronefrosis prenatal, independiente de su grado, puede ser indicativa de malformaciones del tracto genitourinario. Se recomienda un seguimiento estricto en los pacientes con hidronefrosis, incluso en los casos leves, para así detectar tempranamente la presencia o no de malformaciones nefro-urológicas que requieran algún tipo de intervención.

Currently, we do know the clinical repercussions of prenatal hydronephrosis. This study aims to assess the imaging features of hydronephrosis patients and to determine whether the renal pelvis value in the prenatal ultrasound correlates with the presence of urologic malformations and the need for surgery. Materials and methods: Cross sectional study. We evaluated the medical records of all patients almost 5 years old with prenatal hydronephrosis who had consulted during 2006-2010. Results: we analyzed 97 patients, for a total of 135 kidneys. 17.8 % had not hydronephosis; 85.1 % of the patients with pyeloureteral junction stenosis and 90 % of those with posterior urethral valves had been prenatally classified as having mild to severe hydronephrosis. Conversely, 41.4 % of kidneys with vesicouretral reflux were classified as having mild hydronephrosis, 34.5 % moderate and 24.14 % severe. Furthermore, 56.3 % of the evaluated kidneys needed some type of surgery. It is also worth mentioning that it was necessary to perform surgical procedures on 26 % of the kidneys with mild hydronephrosis. Finally, the analysis of the ROC curve made it possible to find that, when the pelvis has an anteroposterior diameter of 10.5 mm, the sensitivity for the detection of nephro-urologic malformations is 67 % and the specificity 71.2 %. Conclusion: prenatal hydronephrosis, regardless of its degree, may be an indication of malformations in the urinary tract. We recommend performing strict follow-ups on the patients to determine the presence of nephro-urologic malformations requiring some kind of intervention.

Síndrome metabólico en niños: problemática, componentes y criterios diagnósticos / Metabolic syndrome in children: issues, components and diagnostic criteria

RESUMEN Antecedentes el síndrome metabólico en niños aumenta el riesgo de diabetes mellitus tipo 2 y enfermedad cardiovascular en la adultez. Objetivo describir los componentes del síndrome metabólico en niños, su prevalencia y criterios diagnósticos propuestos por diferentes organizaciones y autores. Materiales y métodos se realizó una búsqueda bibliográfica en las siguientes bases de datos: Pubmed, Science Direct, Embase, Lilacs y Scielo. Resultados y discusión varias organizaciones han establecido definiciones para diagnosticar el síndrome metabólico en niños, algunas abordando criterios utilizados en adultos o adoptando puntos de corte derivados de poblaciones seleccionadas como niños obesos o sin incluir niños pre-adolescentes, aduciendo en estos últimos una baja prevalencia de alteraciones. Así, la prevalencia de este síndrome en una misma población puede variar (0,9 a 11,4%) según la definición empleada. Sin embargo, dicha prevalencia aumenta con el grado de obesidad infantil y se han demostrado prevalencias altas en pre-púberes, independiente de la clasificación empleada. Recientemente, se propuso usar puntajes continuos para mejorar la evaluación en niños. Conclusión los puntos de corte actualmente empleados ponderan de forma diferente los componentes del síndrome metabólico. Por tanto, se recomienda emplear percentiles según edad, sexo y población para cada componente y evaluar la utilidad de puntajes continuos en esta población.

ABSTRACT Background The metabolic syndrome in children increases the risk for type 2 diabetes and cardiovascular disease in adulthood. Aim To describe the components of metabolic syndrome in children, their prevalence, and diagnostic criteria proposed by different authors and organizations. Materials and methods A literature search of articles published in Pubmed, Science Direct, Embase, Lilacs and Scielo databases was conducted. Results and discussion: Several organizations have established definitions for metabolic syndrome diagnosis in children, some including criteria used for adults or adopting cutoffs derived from selected populations such as obese children or without including pre-adolescent children, arguing a low prevalence of alterations in these. Thus, the prevalence of metabolic syndrome in a particular population varies (0,9% to 11,4%) according to the definition used. However, this prevalence increases according to the obesity grade, and a high prevalence in pre-pubers has been reported, independent of the classification used. Recently, it was proposed the use of a continuous score to improve the metabolic syndrome evaluation in children. Conclusion: The cutoffs currently used give different weighting for each component of metabolic syndrome. Therefore, it is recommended the use of percentiles according to sex and age and population for each component and to evaluate the utility of continuous scores in this population.

Uso de rituximab en pacientes pediátricos con síndrome nefrótico córtico-resistente. Experiencia de un centro / Use of rituximab in pediatric patients with steroidresistant nephrotic syndrome. A single center study / Uso de rituximab em pacientes pediátricos com síndrome nefrótica córtico-resistente. Experiência de um centro

Introducción: los esteroides son el tratamiento de elección del síndrome nefrótico con tasas de éxito hasta del 90%. En pacientes que no responden adecuadamente a ellos, se han usado diferentes esquemas de inmunosupresión. Objetivo y métodos: describir la respuesta terapéutica en un grupo de siete niños con síndrome nefrótico córtico-dependiente (SNCD) o córtico-resistente (SNCR) que recibieron tratamiento con rituximab y micofenolato mofetil en un hospital universitario de la ciudad de Medellín durante los años 2010-2012. Resultados: dos pacientes tenían SNCD y cinco, SNCR; la mediana de edad en el momento del diagnóstico fue de 2 años (p25-75: 1-5); seis meses después de la aplicación del rituximab se encontró disminución de la proteinuria en el 93% de los pacientes; los esteroides se lograron suspender en el 100%; además, disminuyó el número de recaídas; sin embargo, la proteinuria reapareció un año después de dicho tratamiento. Conclusión: con el rituximab disminuyen la proteinuria y la dosis de esteroides, pero la enfermedad recurre 12 meses después de usarlo. Se sugiere hacer otro estudio evaluando el efecto de una segunda dosis de rituximab al año de la primera.

Introduction: Steroids are the cornerstone of therapy for nephrotic syndrome (NS) with a remission rate as high as 90%. In patients who do not respond to them or are steroid dependent, other immunosuppressive drugs have been used. Although rituximab use in NS is off-label, many authors have published their experience with it. Objective and methods: To describe retrospectively a group of seven children with nephrotic syndrome, either steroid-dependent (SDNS) or steroid- resistant (SRNS), treated with rituximab and mycophenolate, at Pablo Tobón Uribe Hospital, in Medellín, Colombia. Results: Two patients with SDNS and five with SRNS were evaluated; median age at diagnosis was 2 years (p25-75: 1-5); six months after treatment with rituximab there was reduction in proteinuria (93%), in the steroid dose (100%) and in the relapse episodes. However, proteinuria reappeared 12 months after treatment. Conclusion: During the first year after rituximab treatment of NS there is reduction in proteinuria and in the steroid dose, but thereafter there is relapse. It is suggested to carry out another study using a second dose of rituximab one year after the first one.

Introdução: os esteroides são o tratamento de eleição da síndrome nefrótica com taxas de sucesso até da 90%. Em pacientes que não respondem adequadamente a eles, usaram-se diferentes esquemas de imunossupressão. Não está aprovado o uso do rituximab em pacientes com síndrome nefrótica, mas alguns grupos publicaram sua experiência com ele nesta doença. Objetivo e métodos: descrever a resposta terapêutica num grupo de sete meninos com síndrome nefrótica córtico-dependente (SNCD) ou córtico -resistente (SNCR) que receberam tratamento com rituximab e micofenolato mofetil num hospital universitário da cidade de Medellín durante os anos 2010-2012. Resultados: dois pacientes tinham SNCD e cinco, SNCR; a idade no momento do diagnóstico foi de 2 anos (p25-75: 1-5); seis meses depois da aplicação do rituximab se encontrou diminuição de 93% da proteinúria e de 100% na dose de prednisolona; ademais, diminuiu o número de recaídas; no entanto, a proteinúria reapareceu um ano depois de dito tratamento. Conclusão: com o rituximab diminuem a proteinúria e a dose de esteroides, mas a doença recorre 12 meses depois de usá-lo. Sugere-se fazer outro estudo avaliando o efeito de uma segunda dose de rituximab no ano seguinte da primeira dose.

Tuberculosis in renal transplant patients: the experience of a single center in Medellín-Colombia, 2005-2013.

INTRODUCTION: Tuberculosis is a common opportunistic infection in renal transplant patients. OBJECTIVE: To obtain a clinical and laboratory description of transplant patients diagnosed with tuberculosis and their response to treatment during a period ranging from 2005 to 2013 at the Pablo Tobón Uribe Hospital. METHODS: Retrospective and descriptive study. RESULTS: In 641 renal transplants, tuberculosis was confirmed in 12 cases. Of these, 25% had a history of acute rejection, and 50% had creatinine levels greater than 1.5 mg/dl prior to infection. The disease typically presented as pulmonary (50%) and disseminated (33.3%). The first phase of treatment consisted of 3 months of HZRE (isoniazid, pyrazinamide, rifampicin and ethambutol) in 75% of the cases and HZME (isoniazid, pyrazinamide, moxifloxacin and ethambutol) in 25% of the cases. During the second phase of the treatment, 75% of the cases received isoniazid and rifampicin, and 25% of the cases received isoniazid and ethambutol. The length of treatment varied between 6 and 18 months. In 41.7% of patients, hepatotoxicity was associated with the beginning of anti-tuberculosis therapy. During a year-long follow-up, renal function remained stable, and the mortality rate was 16.7%. CONCLUSION: Tuberculosis in the renal transplant population studied caused diverse nonspecific symptoms. Pulmonary and disseminated tuberculosis were the most frequent forms and required prolonged treatment. Antituberculosis medications had a high toxicity and mortality. This infection must be considered when patients present with a febrile syndrome of unknown origin, especially during the first year after renal transplant.

Tuberculosis in renal transplant patients: The experience of a single center in Medellín-Colombia, 2005-2013 / Tuberculose em pacientes transplantados renais: experiência de um único centro em Medellín-Colômbia, 2005-2013

Introduction: Tuberculosis is a common opportunistic infection in renal transplant patients. Objective: To obtain a clinical and laboratory description of transplant patients diagnosed with tuberculosis and their response to treatment during a period ranging from 2005 to 2013 at the Pablo Tobón Uribe Hospital. Methods: Retrospective and descriptive study. Results: In 641 renal transplants, tuberculosis was confirmed in 12 cases. Of these, 25% had a history of acute rejection, and 50% had creatinine levels greater than 1.5 mg/dl prior to infection. The disease typically presented as pulmonary (50%) and disseminated (33.3%). The first phase of treatment consisted of 3 months of HZRE (isoniazid, pyrazinamide, rifampicin and ethambutol) in 75% of the cases and HZME (isoniazid, pyrazinamide, moxifloxacin and ethambutol) in 25% of the cases. During the second phase of the treatment, 75% of the cases received isoniazid and rifampicin, and 25% of the cases received isoniazid and ethambutol. The length of treatment varied between 6 and 18 months. In 41.7% of patients, hepatotoxicity was associated with the beginning of anti-tuberculosis therapy. During a year-long follow-up, renal function remained stable, and the mortality rate was 16.7%. Conclusion: Tuberculosis in the renal transplant population studied caused diverse nonspecific symptoms. Pulmonary and disseminated tuberculosis were the most frequent forms and required prolonged treatment. Antituberculosis medications had a high toxicity and mortality. This infection must be considered when patients present with a febrile syndrome of unknown origin, especially during the first year after renal transplant. .

Introdução: A tuberculose é uma infecção oportunista comum em pacientes transplantados renais. Objetivo: Oferecer uma descrição clínica e laboratorial de pacientes transplantados com diagnóstico de tuberculose e sua resposta ao tratamento durante o período entre 2005 e 2013 no Hospital Pablo Tobón Uribe. Métodos: Estudo retrospectivo descritivo. Resultados: Em 641 transplantes renais, a tuberculose foi confirmada em 12 pacientes. Destes, 25% tinham histórico de rejeição aguda e 50% apresentaram níveis de creatinina superiores a 1,5 mg/dl antes da infecção. A patologia geralmente se apresentava como pulmonar (50%) e disseminada (33,3%). A primeira fase do tratamento consistiu de três meses de HZRE (isoniazida, pirazinamida, rifampicina e etambutol) em 75% dos casos e HZME (isoniazida, pirazinamida, moxifloxacina e etambutol) em 25% dos pacientes. Durante a segunda fase do tratamento, 75% dos pacientes receberam isoniazida e rifampicina e 25% isoniazida e etambutol. A duração do tratamento variou entre seis e 18 meses. Em 41,7% dos pacientes, hepatotoxicidade foi associada ao início do tratamento da tuberculose. Durante o seguimento de um ano a função renal manteve-se estável e a taxa de mortalidade foi de 16,7%. Conclusão: A tuberculose foi responsável por diversos sintomas inespecíficos na população de transplantados renais estudada. Tuberculose pulmonar e disseminada foram as formas mais frequentes de acometimento e necessitaram de tratamento prolongado. Medicamentos contra a tuberculose apresentaram alta toxicidade e mortalidade. Esta infecção deve ser considerada quando o paciente apresenta síndrome febril de origem desconhecida, especialmente durante o primeiro ano após o transplante renal. .